IP Verse

Psgl-1 Modulators And Uses Thereof - EP3166636

The patent EP3166636 was granted to Sanford Burnham Medical Research Institute on Apr 7, 2021. The application was originally filed on Jul 8, 2015 under application number EP15819318A. The patent is currently recorded with a legal status of "Revoked".

EP3166636

SANFORD BURNHAM MEDICAL RESEARCH INSTITUTE
Application Number
EP15819318A
Filing Date
Jul 8, 2015
Status
Revoked
Nov 11, 2022
Grant Date
Apr 7, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

REGIMBEAUJan 6, 2022REGIMBEAUADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2002058034
INTERNATIONAL-SEARCH-REPORTUS2009304709
INTERNATIONAL-SEARCH-REPORTUS2012014979
SEARCHUS2005152906

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- LORD et al., "T-bet is required for optimal proinflammatory CD 4+ T- cell trafficking.", Blood, (20051115), vol. 106, no. 10, doi:doi:10.1182/BLOOD-2005-04-1393, pages 3432 - 3439, XP 002523816 [Y] 17, 29, 40 * . Especially pg 3438 col 2 para 2. *-
INTERNATIONAL-SEARCH-REPORT- NISHIMURA et al., Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71., (20090700), vol. 15, no. 7, pages 794 - 797, XP 055383041 [Y] 4, 12, 18 * . Especially abstract, pg 794 col 2 para 2, pg 797 col 1 para 3. *-
INTERNATIONAL-SEARCH-REPORT- SWERS et al., "A high affinity human antibody antagonist of P-selectin mediated rolling.", Biochem Biophys Res Comm, (20061124), vol. 350, no. 3, doi:doi:10.1016/j.bbrc.2006.08.197, pages 508 - 513, XP 024924671 [Y] 8 * . Especially abstract, pg 508 col 2 para 1. *-
INTERNATIONAL-SEARCH-REPORT- URZAINQUI et al., "Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells.", J Immunol, (20071201), vol. 179, no. 11, pages 7457 - 7465, XP 055383047 [Y] 13, 14, 25, 26, 36, 37 * . Especially abstract. *-
INTERNATIONAL-SEARCH-REPORT- AUSTIN et al., "The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH 1 effector populations: a type 1 differentiation bias is also measured in circulating blood T c", J Invest Dermatol, (19991100), vol. 113, no. 5, pages 752 - 759, XP055383547 [Y] 15, 27, 38 * . Especially abstract. *
SEARCH- TINOCO ROBERTO ET AL, "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion", IMMUNITY, CELL PRESS, US, (20160517), vol. 44, no. 5, doi:10.1016/J.IMMUNI.2016.04.015, ISSN 1074-7613, pages 1190 - 1203, XP029537981 [T] 1-15
SEARCH- TOSHIFUMI YAMAOKA ET AL, "The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 64, no. 2, doi:10.1016/J.JDERMSCI.2011.07.005, ISSN 0923-1811, (20110726), pages 99 - 107, (20110805), XP028301978 [A] 1-15
SEARCH- SAORI UMEKI ET AL, "Characterization of monoclonal antibodies against canine P-selectin glycoprotein ligand-1 (PSGL-1)", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 142, no. 1, doi:10.1016/J.VETIMM.2011.04.009, ISSN 0165-2427, (20110413), pages 119 - 125, (20110421), XP028227886 [A] 1-15 * the whole document *
SEARCH- S. ZHANG ET AL, "Targeting CD162 protects against streptococcal M1 protein-evoked neutrophil recruitment and lung injury", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, US, (20131115), vol. 305, no. 10, doi:10.1152/ajplung.00220.2013, ISSN 1040-0605, pages 756 - 763, XP055414695 [I] 1-3,5-11,13-15 * Results and Discussion *
SEARCH- A. HOOS ET AL, "Metastatic Growth Progression Caused by PSGL-1-Mediated Recruitment of Monocytes to Metastatic Sites", CANCER RESEARCH, US, (20140201), vol. 74, no. 3, doi:10.1158/0008-5472.CAN-13-0946, ISSN 0008-5472, pages 695 - 704, XP055414668 [A] 1-15 * Discussion *
SEARCH- C. TRIPODO ET AL, "P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)", CURRENT CANCER DRUG TARGETS, NL, (20090801), vol. 9, no. 5, doi:10.2174/156800909789056971, ISSN 1568-0096, pages 617 - 625, XP055414720 [I] 1-3,5-15 * Results and Discussion *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents